Suppr超能文献

肝脏X受体/共抑制因子复合物在ABCA1和SREBP1基因表达调控中的启动子特异性作用。

Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression.

作者信息

Wagner Brandee L, Valledor Annabel F, Shao Gang, Daige Chris L, Bischoff Eric D, Petrowski Mary, Jepsen Kristen, Baek Sung Hee, Heyman Richard A, Rosenfeld Michael G, Schulman Ira G, Glass Christopher K

机构信息

X-Ceptor Therapeutics, San Diego, California 92121, USA.

出版信息

Mol Cell Biol. 2003 Aug;23(16):5780-9. doi: 10.1128/MCB.23.16.5780-5789.2003.

Abstract

Liver X receptors (LXRs) regulate the expression of genes involved in cholesterol and fatty acid homeostasis, including the genes for ATP-binding cassette transporter A1 (ABCA1) and sterol response element binding protein 1 (SREBP1). Loss of LXR leads to derepression of the ABCA1 gene in macrophages and the intestine, while the SREBP1c gene remains transcriptionally silent. Here we report that high-density-lipoprotein (HDL) cholesterol levels are increased in LXR-deficient mice, suggesting that derepression of ABCA1 and possibly other LXR target genes in selected tissues is sufficient to result in enhanced HDL biogenesis at the whole-body level. We provide several independent lines of evidence indicating that the repressive actions of LXRs are dependent on interactions with the nuclear receptor corepressor (NCoR) and the silencing mediator of retinoic acid and thyroid hormone receptors (SMRT). While dissociation of NCoR and SMRT results in derepression of the ABCA1 gene in macrophages, it is not sufficient for derepression of the SREBP1c gene. These findings reveal differential requirements for corepressors in the regulation of genes involved in cholesterol and fatty acid homeostasis and raise the possibility that these interactions may be exploited to develop synthetic ligands that selectively modulate LXR actions in vivo.

摘要

肝脏X受体(LXRs)调节参与胆固醇和脂肪酸稳态的基因表达,包括ATP结合盒转运体A1(ABCA1)和固醇调节元件结合蛋白1(SREBP1)的基因。LXR的缺失导致巨噬细胞和肠道中ABCA1基因的去抑制,而SREBP1c基因在转录上保持沉默。在此,我们报道LXR缺陷小鼠的高密度脂蛋白(HDL)胆固醇水平升高,这表明在选定组织中ABCA1和可能的其他LXR靶基因的去抑制足以在全身水平上增强HDL的生物合成。我们提供了几条独立的证据表明,LXRs的抑制作用依赖于与核受体共抑制因子(NCoR)以及视黄酸和甲状腺激素受体沉默介质(SMRT)的相互作用。虽然NCoR和SMRT的解离导致巨噬细胞中ABCA1基因的去抑制,但这不足以使SREBP1c基因去抑制。这些发现揭示了共抑制因子在调节参与胆固醇和脂肪酸稳态的基因中的不同需求,并增加了利用这些相互作用开发在体内选择性调节LXR作用的合成配体的可能性。

相似文献

引用本文的文献

8
Remembering your A, B, C's: Alzheimer's disease and ABCA1.牢记基础知识:阿尔茨海默病与ABCA1
Acta Pharm Sin B. 2022 Mar;12(3):995-1018. doi: 10.1016/j.apsb.2022.01.011. Epub 2022 Jan 24.
10
Development of Agonist-Based PROTACs Targeting Liver X Receptor.靶向肝脏X受体的基于激动剂的PROTACs的开发
Front Chem. 2021 May 26;9:674967. doi: 10.3389/fchem.2021.674967. eCollection 2021.

本文引用的文献

2
Identification of macrophage liver X receptors as inhibitors of atherosclerosis.巨噬细胞肝X受体作为动脉粥样硬化抑制剂的鉴定。
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11896-901. doi: 10.1073/pnas.182199799. Epub 2002 Aug 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验